Transatlantic partnership to tackle neurodegenerative disease

July 18, 2013

Research into multiple sclerosis and motor neurone disease is to be boosted with an international collaboration to further understanding of these illnesses.

Experts from the University of Edinburgh and the Massachusetts-based biotechnology company Biogen Idec will work together to seek greater insight into the cell processes behind these debilitating conditions.

This will include identifying drug compounds that could potentially be used as treatments.

The three-year collaboration will combine the University's expertise in translational medicine - which develops laboratory discoveries into treatments for patients - with Biogen Idec's strength in drug discovery and development.

Siddharthan Chandran, Professor of Neurology at the University of Edinburgh's College of Medicine and Veterinary Medicine, said: "This landmark partnership is a brilliant example of academic-industrial collaboration in the field of discovery science. Only by better understanding the biological processes behind these devastating diseases can we hope to discover new and effective therapies."

Clinicians and scientists, based at Edinburgh BioQuarter - Scotland's flagship lifesciences project - will be involved in the project, which will draw on the University's strength in neuroscience, stem cell research and regeneration.

The initiative is being funded by Biogen Idec, which is known for its strength in developing therapies for neurological disorders, particularly its portfolio of treatments for patients with multiple sclerosis.

"We have embraced academic collaborations as a part of our strategy to maintain a vibrant and innovative research organization and better understand the underlying biology of neurodegenerative disease. Our research partnership with the University of Edinburgh is an excellent example of this strategy," said Ken Rhodes, Vice President of Neurology Research at Biogen Idec. "We are committed to continuing to improve the treatment of people with MS and motor neuron diseases, and this collaboration is expected to provide an in-depth portrait of their pathophysiology, and identify important new targets for potential therapies."
-end-


University of Edinburgh

Related Multiple Sclerosis Articles from Brightsurf:

New therapy improves treatment for multiple sclerosis
A new therapy that binds a cytokine to a blood protein shows potential in treating multiple sclerosis, and may even prevent it.

'Reelin' in a new treatment for multiple sclerosis
In an animal model of multiple sclerosis (MS), decreasing the amount of a protein made in the liver significantly protected against development of the disease's characteristic symptoms and promoted recovery in symptomatic animals, UTSW scientists report.

Not all multiple sclerosis-like diseases are alike
Scientists say some myelin-damaging disorders have a distinctive pathology that groups them into a unique disease entity.

New therapeutic options for multiple sclerosis in sight
Strategies for treating multiple sclerosis have so far focused primarily on T and B cells.

Diet has an impact on the multiple sclerosis disease course
The short-chain fatty acid propionic acid influences the intestine-mediated immune regulation in people with multiple sclerosis (MS).

The gut may be involved in the development of multiple sclerosis
It is incompletely understood which factors in patients with multiple sclerosis act as a trigger for the immune system to attack the brain and spinal cord.

Slowing the progression of multiple sclerosis
Over 77,000 Canadians are living with multiple sclerosis, a disease whose causes still remain unknown.

7T MRI offers new insights into multiple sclerosis
Investigators from Brigham and Women's Hospital have completed a new study using 7 Tesla (7T) MRI -- a far more powerful imaging technology -- to further examine LME in MS patients

How to improve multiple sclerosis therapy
Medications currently used to treat multiple sclerosis (MS) can merely reduce relapses during the initial relapsing-remitting phase.

Vaccinations not a risk factor for multiple sclerosis
Data from over 12,000 multiple sclerosis (MS) patients formed the basis of a study by the Technical University of Munich (TUM) which investigated the population's vaccination behavior in relation to MS.

Read More: Multiple Sclerosis News and Multiple Sclerosis Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.